Effect of the probiotic bacterium Escherichia coli Nissle 1917 on symptom pattern and immunologic function in patients suffering from irritable bowel syndrome with diarrhoea

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000205932

Enrollment

Registered

2011-02-22

Start date

2009-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

. .

Interventions

Probiotic bacteria E.coli Nissle (Mutaflor) will be orally administered to the participant. 1 tablet, 100mg for 4 days and then 2 tablets, 200mg for the next 17 days.Treatment of probiotic bacteria tablet will commence post a permability test which includes a 24hr urine save.

Study design

Allocation

Non-randomised trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

symptoms consistent with diarrhoea predominant IBS according to the Rome III criteria;not received antibiotics 4 weeks prior ;not taking immunosuppressive medication;not taking laxatives and prokinetic drugs for 2 weeks;able to sign consent;

Exclusion criteria

Eligible Particpants will be deemed healthy unless they have the following..previous abdominal or gynaecologyical surgery (except appendectomy and cholecystectomy); previous gastrointestinal cancer;history of other diseases known to affect colonic motility; known peptic ulcer disease;

Outcome results